Global Dry Eye Syndrome Market 2015-2019
About dry eye syndrome
Dry eye syndrome usually results in dryness of eyes due to deficient tear production or quick tear evaporation or deviation in tear uniformity. This syndrome is of two types: aqueous tear deficient dry eye and evaporative dry eye. In aqueous tear deficient dry eye, lacrimal glands do not produce enough tears, whereas meibomian gland dysfunction results in evaporative dry eye. Meibomian glands secrete lipids to slow tear evaporation and maintain tear stability. The symptoms include pain, redness, burning, and fatigue in the eye and decreased tolerance to continuous visual activity. Dry eye syndrome cannot be cured, but symptoms can be controlled. Teardrops and anti-inflammatory drugs are used in the treatment.
Technavio's analysts forecast the global dry eye syndrome market to grow at a CAGR of 4.75% over the period 2014-2019.
Covered in this report
The report includes the present scenario and the growth prospects of the global dry eye syndrome market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of teardrops and anti-inflammatory drugs used in the treatment of dry eye syndrome. Technavio's report, Global Dry Eye Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Dry Eye Syndrome Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Dry Eye Syndrome Market: Alcon, Allergan, Otsuka Holdings and Santen Pharmaceuticals
Other Prominent Vendors in the market are: Acadia Pharmaceuticals, Aciex, Allostera Pharma, arGentis, Auven Therapeutics (Celtic), Bridge Pharma, Can-Fite and Cellzome
Commenting on the report, an analyst from Technavio’s team said: “There is no cure for dry eye; current treatment options offer only symptomatic relief. In addition, these therapies do not address the quality of the tears. Thus, there is a need for new drugs that control inflammation with improved efficacy or stimulate mucin and tear secretion. The current pipeline agents are aimed at controlling inflammation and restoring the normal amount of tears. Many of these pipeline candidates exhibit novel mechanisms of action. The approval of late-stage clinical molecules is expected to serve the needs of patients, thereby propelling market growth. These therapies might act alone or in combination with other therapies to provide more effective solutions for dry eye syndrome.”
According to the report, changes in lifestyle, especially the increased usage of electronic gadgets such as computers and TV has led to a significant rise in the number of cases of dry eye syndrome. Excessive eye contact with these devices results in strain on the eyes, diminishing visual alertness, and mucosal dryness or eye burning. Continuous and prolonged staring results in an incomplete eye blink, which in turn decreases the stability of the tear film, breaking it and causing ocular discomfort. Therefore, the increased adoption of lifestyle changes leading to dry eye syndrome will drive the market growth.
Further, the report states that reliance on self-medication is a major challenge in the market.
Alcon, Allergan, Otsuka Holdings, Santen Pharmaceuticals, Acadia Pharmaceuticals, Aciex, Allostera Pharma, arGentis, Auven Therapeutics (Celtic), Bridge Pharma, Can-Fite, Cellzome
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook